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provided similar results within acceptable thresholds for
willingness-to-pay (Incremental Cost-Effectiveness Ratio [ICER]
< 35,000, €50,000 or $50,000/QALY). Contrasting results
were, however, found in the etanercept studies. In 3 cases,
etanercept-MTX combination was found to be a cost-effective
strategy compared to other DMARDs (generally MTX alone). In
the other 3 economic evaluations, etanercept (as monotherapy or
in combination with MTX) was not cost-effective compared to
standard DMARDs. CONCLUSION: The review found a pre-
ponderance of cost-effectiveness analyses. Differences in etaner-
cept results appear be due to differences in model structure and
underlying modelling assumptions. This ﬁnding is consistent
with a recent review of inﬂiximab cost-effectiveness analyses.
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OBJECTIVES: The most common treatments for psoriatic
arthritis (PsA) are non steroidal anti-inﬂammatory drugs
(NSAIDs), COX-2 inhibitors, corticosteroids and disease-
modifying antirheumatic drugs (DMARDs). Recently, anti-
TNF-a drugs have been introduced as second line treatments of
PsA. Scope of this study is cost-effectiveness (CEA) and cost-
utility (CUA) analysis of etanercept, inﬂiximab and adalimumab
in the perspective of the Italian National Health System (NHS).
METHODS: A Markov model has been structured in 5 states
describing the clinical condition according to ACR scale: basal
(ACR < 20), ACR20–49, ACR50–69, ACR70–100, failure of
treatment. The transition parameters derived from three different
Phase III pivotal studies of etanercept, inﬂiximab and adali-
mumab versus placebo. The effectiveness was estimated by inte-
grating time with the ACR level (ACRAWs—ACR-Adjusted
Weeks). Utilities were estimated by the correlation of ACR with
HUI-3 and EQ-5D scales. The Markov cycle was 1 week and the
time horizon of the simulation 1 year. RESULTS: One-year treat-
ment cost of etanercept, adalimumab and inﬂiximab for the
Italian NHS are Euro 7,668, Euro 8,354 and Euro 12,631,
respectively. During the same period a gain of 12.67 ACRAWs,
15.11 ACRAWs and 16.20 ACRAWs is obtained with the three
therapies, respectively. C/E ratios of etanercept, adalimumab and
inﬂiximab are 605 Euro/ACRAW, 553 Euro/ACRAW, and 780
Euro/ACRAW, respectively. The treatment with etanercept, adali-
mumab or inﬂiximab induce a gain of 0.1037 QALYs, 0.1241
QALYs and 0.1330 QALYs, respectively, when the utility index is
HUI-3 and a gain of 0.0833 QALYs, 0.0946 QALYs and 0.1020
QALYs, when the utility index is EQ-5D. The C/U ratios of
etanercept are 73,966 Euro/QALY(HUI3) and 92,091 Euro/
QALY(EQ5D), those of adalimumab 67,340 Euro/QALY(HUI3)
and 88,274 Euro/QALY(EQ5D), and those of inﬂiximab 94,940
Euro /QALY(HUI3) and 123,858 Euro/QALY(EQ5D). CON-
CLUSION: The three anti-TNF-a drugs produce different levels
of effectiveness and costs but no strategy is clearly dominated by
any other.
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OBJECTIVES: To determine the cost-effectiveness of introducing
leﬂunomide to standard disease modifying antirheumatic drugs
(DMARD) in rheumatoid arthritis in Poland. METHODS: A
Markov model representing combination of four most popular
DMARD sequences in Poland was developed (based on methotr-
exate, sulphasalazine, chloroquine and cyclosporin). DMARD
sequences including leﬂunomide were compared with those
excluding leﬂunomide. Efﬁcacy, measured according to Ameri-
can College of Rheumatology criteria and Health Assessment
Questionnaire-based utility, was derived from literature review.
Only direct medical costs, measured from the perspective of
National Health Fund were included. Different reimbursement
scenarios were compared. Model time horizon was 25 years.
Cost and beneﬁts were discounted at 5% per year and were
subject to sensitivity analysis (values in Polish zloty (PLN): 1
Euro = 3.8 PLN). RESULTS: Introduction of leﬂunomide into
the standard DMARD sequences resulted in a gain of 0.740
ACR20-, 0.406 ACR50-, 0.211 ACR70 response and 0.171
QALY at an additional cost of 3,164 PLN per patient (corre-
sponding incremental cost-effectiveness ratio (ICER) 18,453
PLN/QALY). In the optimistic and pessimistic scenarios ICER
was estimated at 5,752 PLN/QALY and 37,653 PLN/QALY,
respectively. When only costs were discounted ICER diminished
to 28,714 PLN/QALY and when discounting was not
performed—to 19,558 PLN/QALY. CONCLUSION: Leﬂuno-
mide as an additional option in a DMARD treatment sequences
is cost-effective in rheumatoid arthritis in Poland. Limiting
cyclosporin reimbursement by cheaper leﬂunomide would result
in savings of 3,194 PLN per patient.
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OBJECTIVES: Nonsteroidal anti-inﬂammatory drugs (NSAID)
are frequently used in Czech Republic for pain symptoms asso-
ciated with osteoarthritis (OA). The annual consumption of
NSAID reaches almost 1 billion CZK (36 million €). Non-
selective cyclooxygenase (COX) inhibitors (e.g. diclofenac, ibu-
profen) are mostly prescribed but often cause gastrointestinal
side effects, including life threatening ulceration, perforation or
bleeding (PUB). We assessed direct health care costs of meloxi-
cam (preferential COX-2 inhibitor, daily dose 7.5 mg) versus
piroxicam (20 mg/day) and diclofenac (100 mg/day) based
on two large-scale clinical trials (MELISSA and SELECT).
METHODS: A model based on both studies with meloxicam and
published in literature was used. It included acquisition costs for
medications and costs for management of adverse events (AE).
To identify medical practice in AE management—especially PUB,
a questionnaire was prepared to collect data from gastroenterol-
ogy departments. Eight departments were involved in a retro-
spective data acquisition; these data were translated into
weighted average costs of particular AE treatments. The 2006
prices were used to assess direct medical costs. RESULTS:
Among most costly AEs were gastrointestinal ulceration—mean
costs per patient 160€ (118–225€), bleeding and penetration of
ulcer—934€ (281–1362€) and ulcer perforation 2342€ (1542–
3011€). If gastrointestinal complications of diverse severity were
taken into account, mean costs (per patient treated for 28 days)
for piroxicam were 10.4€, for diclofenac 10.6€ and meloxicam
7.8€. Costs for AE management represented 70–80% of these
costs in non-selective drugs and almost 60% of meloxicam total
costs. CONCLUSION: Management of gastrointestinal AEs gen-
erates a signiﬁcant cost driver of total treatment costs in NSAID
A246 Abstracts
users. The higher incidence of severe complications with non-
selective NSAID resulted, despite of a lower acquisition price, in
higher costs of those medications compared to meloxicam.
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OBJECTIVES: To compare, in the Spanish setting, the annual
costs associated with the management of adult patients with
rheumatoid arthritis using oral leﬂunomide (Arava®) or a new
presentation of metotrexate (Metoject®, preﬁlled syringes).
METHODS: Due to the absence of any randomized controlled
trial that had showed signiﬁcant differences in effectiveness
between leﬂunomide and metotrexate a cost-minimization analy-
sis has been performed under the Spanish societal perspective.
Data about effectiveness and dose of drugs administered were
obtained from the clinical trial US310, a 12 months-randomised
controlled trial which compares head-to-head 20 mg daily of
leﬂunomide versus 7.15–15 mg weekly of metotrexate. Use of
other medical resources like lab tests and consultations related
with drug monitoring were derived from the manufacturers’
summary of product characteristics. Patient time and productiv-
ity time lost were derived from other published studies and
economic evaluations. RESULTS: Annual drug costs with
leﬂunomide and preﬁlled syringes of metotrexate are 1,112.52€
and 1,438.91€ respectively. Annual monitoring costs amount
680.76€ and 710.26€ respectively. Other direct medical costs
equal up to 677€ and 542€ while indirect costs amount 862€ and
577€ respectively. CONCLUSION: Metoject®, a new presenta-
tion of metotrexate has been recently launched in Spain. The
signiﬁcant rise in price of Metoject® compared with other pre-
sentations of metotrexate justiﬁes performing an economic evalu-
ation comparing it with the administration of oral leﬂunomide
(Arava®). Arava® has lower drug and monitoring related costs
than Metoject®, while not statistically signiﬁcant differences in
other direct and indirect costs have been observed between the
treatments.
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OBJECTIVES: Rituximab is an anti-CD20 monoclonal antibody
with demonstrated efﬁcacy for patients with rheumatoid arthritis
who had inadequate response to anti-TNF therapies (Cohen
et al. 2005). The primary objective of this analysis was to esti-
mate the total cost of rituximab therapy and to compare it with
inﬂiximab, adalimumab and etanercept under a private payer
perspective in Brazil. A budget impact analysis (BIA) of the
incorporation of rituximab was also performed. METHODS: We
assumed the same efﬁcacy for the comparators as there is not any
head-to-head clinical trial available until date and indirect com-
parisons showed higher ACR response rates for Mabthera.
Direct annual medical costs for biological drugs, IV administra-
tion, weekly metotrexate (MTX) and routine exams were taken
from a Delphi panel with Brazilian rheumatologists. Base case
dosages considered were: rituximab (2 g at every 8 months),
inﬂiximab (4 mg/kg at weeks 0, 2, 6 and then at every 8 weeks);
adalimumab (40 mg every other week) and etanercept (50 mg
per week). Local administration costs were obtained from Schei-
nberg et al. (2005). Costs were reported in 2007 Brazilian Reais
and discounted at a 5% rate in the BIA. Therapies were evaluated
using a 5-year horizon. In order to assess uncertainty, one and
two-way sensitivity analyses were also performed. RESULTS: In
the base case scenario, rituximab therapy resulted in a total
annual cost of R$ 45,647 per patient. Total annual costs per
patient for inﬂiximab, adalimumab and etanercept were R$
78,638; R$ 89,943 and R$ 119,170 respectively. In the BIA,
rituximab therapy resulted in total savings of R$ 91,006,061 in
5 years. Results were sensitive to dosage schedule (rituximab and
inﬂiximab) and drug acquisition costs. CONCLUSION: Results
suggest that therapy with rituximab is a cost-saving alternative
for patients with rheumatoid arthritis in the Brazilian private
health care system, unfettering resources for other disease areas.
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OBJECTIVES: Evaluate the impact of co-morbidity on the real
world health care costs of rheumatoid arthritis (RA) patients
who received anti-tumor necrosis factor (anti-TNF) therapy.
METHODS: A retrospective study was conducted using the
HealthCore Integrated Research Database from Blue Cross Blue
Shield plans. The study population consisted of RA patients
initiating anti-TNF therapy (adalimumab, etanercept or inﬂix-
imab) between January 1, 2003 and June 30, 2005 (index date).
All patients had >=6 months continuous plan enrollment before
and >=12 months after the index date of initiating anti-TNF
therapy. All-cause health care costs (inpatient, emergency depart-
ment visits, ofﬁce visits, outpatient services, non-TNF prescrip-
tion drugs) were calculated for the 6-month baseline pre- and
12-month post-index periods. A generalized linear model was
developed to assess the association between comorbidity burden,
as assessed by the Charlson Co-morbidity Index (CCI), and total
all-cause health care costs post-index period while controlling
for other potential confounding variables. Comparisons were
made between two mutually exclusive cohorts based on the
co-morbidity level, DCI > 0 vs. DCI = 0 (no co-morbidity).
RESULTS: In total, 2405 RA patients were analyzed; 71% were
female and the mean age was 48 years. During the 6 month
pre-index period, 16% of patients were identiﬁed with osteoar-
thritis, 12% with hypertension, 8% with diabetes, and 4.5%
with cardiovascular events. After adjusting for baseline all-cause
health care costs, age, gender, anti-TNF use, and several comor-
bidities of interest (osteoarthritis, hypertension, diabetes, and
cardiovascular events), patients in the DCI > 0 cohort (n = 1832)
had 12% higher total all-cause health care costs ($6795 vs.
$6072) compared with patients in the DCI = 0 cohort (n = 573)
after initiation of anti-TNF therapy (P < 0.0001). CONCLU-
SION: High co-morbidity burden among RA patients on anti-
TNF therapy is associated with an increase in total all-cause
health care costs. Additional analyses are recommended to deter-
mine the clinical, economic and humanistic outcomes associated
with the use of anti-TNF therapies.
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